Name | Juliette Manor |
---|---|
Location | 482 Oak Street, Berlin, Wisconsin |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 37 |
Occupancy Rate | 106.22% |
Medicare ID (CCN) | 525286 |
Legal Business Name | Thedacare Medical Center- Berlin Inc |
Ownership Type | Non Profit - Corporation |
NPI Number | 1023154929 |
Organization Name | THEDACARE MEDICAL CENTER - BERLIN, INC. |
Doing Business As | JULIETTE MANOR |
Address | 482 Oak St, Berlin, WI 54923 |
Phone Number | 920-361-3092 |
News Archive
Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment regimens, including treatment with the drugs lenalidomide and bortezomib, and in whom the last treatment had no sufficient effect.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Many cancer patients in Europe are being denied access to adequate pain relief because of over-zealous regulations restricting the availability and accessibility of opioid-based drugs such as morphine.
Varian Medical Systems, Inc., X-Ray Products, will be showcasing a comprehensive imaging portfolio of PaxScan® digital image detectors and X-ray tubes for fluoroscopy, angiography, cardiology and cone-beam CT imaging at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria this week.
Scientists at the Centre for Addiction and Mental Health have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord related to MS, and a way to alter this change to reduce the nerve cell damage that occurs with the disease.
› Verified 3 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment regimens, including treatment with the drugs lenalidomide and bortezomib, and in whom the last treatment had no sufficient effect.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Many cancer patients in Europe are being denied access to adequate pain relief because of over-zealous regulations restricting the availability and accessibility of opioid-based drugs such as morphine.
Varian Medical Systems, Inc., X-Ray Products, will be showcasing a comprehensive imaging portfolio of PaxScan® digital image detectors and X-ray tubes for fluoroscopy, angiography, cardiology and cone-beam CT imaging at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria this week.
Scientists at the Centre for Addiction and Mental Health have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord related to MS, and a way to alter this change to reduce the nerve cell damage that occurs with the disease.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.39 | 14.46 |
Percentage of long-stay residents who lose too much weight | 2.74 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 18.37 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.15 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.41 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.2 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 87.91 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 4.4 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.06 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 33.26 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.5 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 12.28 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 87 | 95.98 |
Percentage of short-stay residents who made improvements in function | 69.57 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.5 | 82.93 |
News Archive
Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment regimens, including treatment with the drugs lenalidomide and bortezomib, and in whom the last treatment had no sufficient effect.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
Many cancer patients in Europe are being denied access to adequate pain relief because of over-zealous regulations restricting the availability and accessibility of opioid-based drugs such as morphine.
Varian Medical Systems, Inc., X-Ray Products, will be showcasing a comprehensive imaging portfolio of PaxScan® digital image detectors and X-ray tubes for fluoroscopy, angiography, cardiology and cone-beam CT imaging at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria this week.
Scientists at the Centre for Addiction and Mental Health have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord related to MS, and a way to alter this change to reduce the nerve cell damage that occurs with the disease.
› Verified 3 days ago